Sigilon Therapeutics is a biopharmaceutical company creating functional cures for chronic diseases using Shielded Living Therapeutics. The Shielded Living Therapeutics product platform consists of novel engineered human cells that are encased in a proprietary immune-shielding matrix and placed in the body. These Shielded Living Therapeutics then produce therapeutic proteins in a programmable and durable fashion, without generating fibrosis or immune rejection. Our pipeline of products in hemophilia, lysosomal storage diseases, and, in collaboration with Eli Lilly, type 1 diabetes, are rapidly advancing toward the clinic. Sigilon was founded and created by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology. Please forward your application via email to email@example.com
As our lead programs advance into clinical development in 2019, Sigilon is looking for experienced process development scientists to join the team responsible for enhancing and evolving the manufacturing process for Sigilon’s encapsulated allogeneic cell therapy platform. Key objectives will be to develop robust and scalable cell therapy bioprocesses and transfer these processes to contract manufacturing partners.